IPSIndian Journal of Pharmacology
Home  IPS  Feedback Subscribe Top cited articles Login 
Users Online : 760 
Small font sizeDefault font sizeIncrease font size
Navigate Here
  Search
 
  
Resource Links
   Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
   Article in PDF (330 KB)
   Citation Manager
   Access Statistics
   Reader Comments
   Email Alert *
   Add to My List *
* Registration required (free)

 
In This Article
   References

 Article Access Statistics
    Viewed112    
    Printed0    
    Emailed0    
    PDF Downloaded2    
    Comments [Add]    

Recommend this journal

 


 
 Table of Contents    
LETTER TO THE EDITOR
Year : 2021  |  Volume : 53  |  Issue : 2  |  Page : 173
 

Unmet needs of corneal collagen cross-linking


Attar Sain Jain Hospital, New Delhi, India

Date of Submission21-Jul-2019
Date of Decision07-Oct-2019
Date of Acceptance26-Apr-2021
Date of Web Publication26-May-2021

Correspondence Address:
Dr. Tapasya Singha
Attar Sain Jain Hospital, Lawrence Road, New Delhi - 110 035
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/ijp.IJP_450_19

Rights and Permissions



How to cite this article:
Singha T. Unmet needs of corneal collagen cross-linking. Indian J Pharmacol 2021;53:173

How to cite this URL:
Singha T. Unmet needs of corneal collagen cross-linking. Indian J Pharmacol [serial online] 2021 [cited 2021 Jun 13];53:173. Available from: https://www.ijp-online.com/text.asp?2021/53/2/173/316951




Sir,

The study titled, “Safety and efficacy of riboflavin assisted collagen cross-linking of cornea in progressive keratoconus patients: A prospective study in North East India” by Bhattacharyya et al., has been nicely conducted by the authors.[1] The two novelty factors addressed by the authors were evaluation in “north eastern participants” and use of “progressive keratoconus” population. Again, this study is one of the few studies addressing contrast sensitivity issue. Collagen cross-linking (CXL) is a rapidly progressing and relatively new field. In this context, I want to highlight some unmet needs in the field of corneal collagen cross-linking.

  1. Dresden protocol uses two agents (riboflavin + UV-A) for corneal collagen cross-linking, and it is unknown whether cross-linking is a primary effect of riboflavin or UV-A and individual effect sizes of the two agents are not evaluated clinically till now[2]
  2. Till now, only one study has evaluated the long-term outcome of corneal CXL procedure (retrospective analysis of data 10 years duration).[3] We need more long-term studies for the evaluation of long-term visual and topographic outcomes and need of repeat cross-linking in both keratoconus and progressive population
  3. Comparative efficacy and safety of different cross-linking protocols need to be evaluated in randomized controlled trial settings for evidence-based selection of a single protocol
  4. Anterior segment optical coherence tomography-based detailed evaluation of C3R patients on different protocols and their correlation to vision may be done
  5. Comparative evaluation of different riboflavin formulation and their comparative penetration and therapeutic efficacy may be addressed in further studies.


Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.



 
  References Top

1.
Bhattacharyya A, Sarma P, Das K, Agarwal B, Medhi J, Das Mohapatra SS. Safety and efficacy of riboflavin-assisted collagen cross-linking of cornea in progressive keratoconus patients: A prospective study in North East India. Indian J Pharmacol 2019;51:157-67.  Back to cited text no. 1
  [Full text]  
2.
Wollensak G. Crosslinking treatment of progressive keratoconus: New hope. Curr Opin Ophthalmol 2006;17:356-60.  Back to cited text no. 2
    
3.
Theuring A, Spoerl E, Pillunat LE, Raiskup F. Corneal collagen cross-linking with riboflavin and ultraviolet-A light in progressive keratoconus. Results after 10-year follow-up. Ophthalmologe 2015;112:140-7.  Back to cited text no. 3
    




 

Top
Print this article  Email this article
 

    

Site Map | Home | Contact Us | Feedback | Copyright and Disclaimer
Online since 20th July '04
Published by Wolters Kluwer - Medknow